JAPAN DIABETES CARE DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, and Forecasts (2023 - 2028)

The Japan Diabetes Care Devices Market is segmented into Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring). The report offers the value (in USD million) for the above segments.

Japan Diabetes Care Devices Industry Overview

Japan Diabetes Devices Market Summary
Study Period: 2018 - 2028
CAGR: > 3 %

Major Players

Japan Diabetes Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Japan Diabetes Care Devices Market Analysis

The Japan Diabetes Care Devices Market was valued at USD 7.6 billion in 2021, and it is expected to reach more than USD 9 billion by 2027, registering a CAGR of more than 3% during 2022- 2027.

The COVID-19 pandemic has had a substantial impact on the diabetes care devices market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of diabetes care devices. A retrospective analysis was presented at the virtual 81st Scientific Sessions of the American Diabetes Association® (ADA) which showed diabetes was the main risk factor for the accelerated advancement to a severe state in Japanese COVID-19 patients.
Throughout the pandemic, diabetes has persisted as a significant risk factor for COVID-19. In hospitalized patients with diabetes and COVID-19, one in 10 people died within seven days of admission.

The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the Japanese diabetes care device market's growth.

Diabetes has emerged as a global epidemic, Japan has around 11 million people with diabetes according to IDF 2021 data. While Type 1 diabetes is caused by an immune system malfunction, Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Hence, Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes. Japan has one of the largest elderly populations in the world which is more susceptible to the onset of type 2 diabetes. As Japan’s population continues to age, the prevalence of diabetes increases as well. The monitoring and management of blood glucose levels are on the rise, to avoid negative consequences, such as cardiovascular diseases, kidney disorders, and many other conditions. ​ ​

Japan Diabetes Care Devices Industry Segments

The Japan Diabetes Care Devices Market is segmented into Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring). The report offers the value (in USD million) for the above segments.

Monitoring Devices (Value and Volume, 2016-2027)
Self-monitoring Blood Glucose Devices
Glucometer Devices
Blood Glucose Test Strips
Lancets
Continuous Glucose Monitoring Devices
Sensors
Durables (Receivers and Transmitters)
Management Devices (Value and Volume, 2016-2027)
Insulin Delivery Devices
Insulin Pumps
Insulin Pump Monitor
Insulin Pump Reservoir
Insulin Infusion Sets
Insulin Syringes
Insulin Disposable Pens
Insulin Cartridges in Reusable Pens
Jet Injectors

Report scope can be customized per your requirements. Click here.

Japan Diabetes Care Devices Market Trends

This section covers the major market trends shaping the Japan Diabetes Care Devices Market according to our research experts:

Continuous Glucose Monitoring Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period

Continuous Glucose Monitoring Segment recorded more than USD 130 million in revenue in 2021, which is expected to further increase with a CAGR of more than 13% during the forecast period.

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period. The prevalence of diabetes is growing among all ages in Japan, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles. The prevalence of diabetes in adults is around 7% in Japan. ​Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients. The Japanese healthcare system has a few disease management programs conducted by the Japan Association for Diabetes Education and Care. Japan is one of the regional leaders in Asia-Pacific, in terms of diabetic public health policies.

The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness. Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies, like cell phone integration, which is likely to drive the segment growth during the forecast period.

Japan Diabetes Care Devices Market: Revenue in USD Million, by CGM, 2022 - 2027

Insulin cartridges in reusable pens Occupied the Highest Share in the Management Devices Segment in 2021

Insulin cartridges in reusable pens occupied the highest market share of about 64% in the management devices segment in 2021.

Insulin cartridges in reusable pens currently have the highest demand among all insulin delivery devices in the Japanese market. Insulin cartridges in reusable pens are an upgraded version of insulin vials. Most types of insulins are manufactured in the form of cartridges, making them easily accessible. These devices have all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens in the long run. Due to the increasing demand for insulin cartridges, most insulin device manufacturing companies have produced reusable insulin pens that are compatible with various insulin manufacturers' cartridges. These insulin cartridges are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on the go. Cartridges that are open do not need to be refrigerated, making storage very easy for consumers. Thus, cartridges are the most cost-effective way to use insulin, as reusable pens are a one-time investment, unlike disposable pens.

Diabetes has been identified as a healthcare priority by the Ministry of Health, Labour and Welfare (MHLW). The high prevalence of type 2 diabetes is associated with a significant economic burden. The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidemia and in patients who develop complications. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan. Also, insulin therapy by self-injection became legal and is covered by health insurance. Such advantages have helped the rise in the adoption of these products in the Japanese market.

Japan Diabetes Care Devices Market: Revenue in USD Million, by Insulin Cartridges in Reusable Pens, 2022-2027

Japan Diabetes Care Devices Market Competitor Analysis

The Japanese diabetes care devices market has been driven by constant innovations by manufacturers like Roche, Abbott, Novo Nordisk, Dexcom, and Medtronic to compete and struggle in the market. The major companies are partnering with each other to develop new technologies in diabetes care devices, which is likely to drive the market in the future.

Japan Diabetes Care Devices Market Top Players

  1. F. Hoffmann-La Roche Ltd

  2. Abbott Diabetes Care

  3. Novo Nordisk

  4. Dexcom

  5. Medtronic

*Disclaimer: Major Players sorted in no particular order

Japan Diabetes Devices Market Concentration

Japan Diabetes Care Devices Market Recent Developments

  • In June 2022, Sanofi and Health2Sync announced that they will work together on new features such as connected caps for insulin products that can automatically record delivered doses, rather than requiring them to be logged manually, and titration alerts from the app to indicate when a change in insulin dose may be required.
  • In March 2022, Quantum Operation Inc., a Tokyo-based healthcare IoT startup, presented the world’s first non-invasive glucose monitor capable of continuous measurement. It measures the blood sugar from the wrist without any pricks.

Japan Diabetes Care Devices Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Monitoring Devices (Value and Volume, 2016-2027)

      1. 5.1.1 Self-monitoring Blood Glucose Devices

        1. 5.1.1.1 Glucometer Devices

        2. 5.1.1.2 Blood Glucose Test Strips

        3. 5.1.1.3 Lancets

      2. 5.1.2 Continuous Glucose Monitoring Devices

        1. 5.1.2.1 Sensors

        2. 5.1.2.2 Durables (Receivers and Transmitters)

    2. 5.2 Management Devices (Value and Volume, 2016-2027)

      1. 5.2.1 Insulin Delivery Devices

        1. 5.2.1.1 Insulin Pumps

          1. 5.2.1.1.1 Insulin Pump Monitor

          2. 5.2.1.1.2 Insulin Pump Reservoir

          3. 5.2.1.1.3 Insulin Infusion Sets

        2. 5.2.1.2 Insulin Syringes

        3. 5.2.1.3 Insulin Disposable Pens

        4. 5.2.1.4 Insulin Cartridges in Reusable Pens

        5. 5.2.1.5 Jet Injectors

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2016-2027)

    2. 6.2 Type 2 Diabetes Population (2016-2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Abbott Diabetes Care

      2. 7.1.2 F. Hoffmann-La Roche Ltd

      3. 7.1.3 Johnson & Johnson (LifeScan)

      4. 7.1.4 Arkray

      5. 7.1.5 Ascensia Diabetes Care

      6. 7.1.6 Sanofi

      7. 7.1.7 Dexcom

      8. 7.1.8 Medtronic

      9. 7.1.9 Novo Nordisk AS

      10. 7.1.10 Becton Dickinson

      11. 7.1.11 Eli Lilly

      12. 7.1.12 Ypsomed Holding AG

      13. 7.1.13 Terumo

    2. 7.2 Company Share Analysis

      1. 7.2.1 Monitoring Devices

        1. 7.2.1.1 Medtronic

        2. 7.2.1.2 Dexcom

        3. 7.2.1.3 Abbott Diabetes Care

        4. 7.2.1.4 Others

      2. 7.2.2 Management Devices

        1. 7.2.2.1 Medtronic

        2. 7.2.2.2 Insulet Corporation

        3. 7.2.2.3 Tandem

        4. 7.2.2.4 F. Hoffmann-La Roche Ltd

        5. 7.2.2.5 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Japan Diabetes Care Devices Market Research FAQs

The Japan Diabetes Care Devices Market is studied from 2018 - 2028.

The Japan Diabetes Care Devices Market is growing at a CAGR of >3% over the next 5 years.

The Japan Diabetes Care Devices Market is valued at 7 Billion USD in 2018.

The Japan Diabetes Care Devices Market is valued at 9 Billion USD in 2028.

F. Hoffmann-La Roche Ltd, Abbott Diabetes Care, Novo Nordisk, Dexcom, Medtronic are the major companies operating in Japan Diabetes Care Devices Market.

Japan Diabetes Care Devices Industry Reports

In-depth industry statistics and market share insights of the Japan Diabetes Care Devices sector for 2020, 2021, and 2022. The Japan Diabetes Care Devices research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Japan Diabetes Care Devices report PDF.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!